Physician-assisted death: A Canada-wide survey of ALS health care providers.

Neurology

From Sunnybrook Health Sciences Centre (A.A., H.P., A.I., W.K., N.P., A.T., L.Z.), University of Toronto, Canada; Universidade Federal de São Paulo (A.A.), Brazil; Critical Care and Palliative Care (J.D.), University Health Network, Toronto; Clinic of Neuromuscular & Neurogenetic Diseases (N.D.), CHU de Québec, Faculty of Medicine, Laval University; Department of Clinical Neurosciences (L.K.), Hotchkiss Brain Institute, University of Calgary; Dalhousie University Faculty of Medicine (C.O.), Stan Cassidy Centre for Rehabilitation; Department of Clinical Neurological Sciences (C.S.), Schulich School of Medicine and Dentistry, University of Western Ontario, Canada; and Division of Rheumatology (A.B.V.-S.), Internal Medicine Department, Universidade do Estado do Rio de Janeiro, Brazil.

Published: September 2016

Objective: To survey amyotrophic lateral sclerosis (ALS) health care providers to determine attitudes regarding physician-assisted death (PAD) after the Supreme Court of Canada (SCC) invalidated the Criminal Code provisions that prohibit PAD in February 2015.

Methods: We conducted a Canada-wide survey of physicians and allied health professionals (AHP) involved in the care of patients with ALS on their opinions regarding (1) the SCC ruling, (2) their willingness to participate in PAD, and (3) the PAD implementation process for patients with ALS.

Results: We received 231 responses from ALS health care providers representing all 15 academic ALS centers in Canada, with an overall response rate for invited participants of 74%. The majority of physicians and AHP agreed with the SCC ruling and believed that patients with moderate and severe stage ALS should have access to PAD; however, most physicians would not provide a lethal prescription or injection to an eligible patient. They preferred the patient obtain a second opinion to confirm eligibility, have a psychiatric assessment, and then be referred to a third party to administer PAD. The majority of respondents felt unprepared for the initiation of this program and favored the development of PAD training modules and guidelines.

Conclusions: ALS health care providers support the SCC decision and the majority believe PAD should be available to patients with moderate to severe ALS with physical or emotional suffering. However, few clinicians are willing to directly provide PAD and additional training and guidelines are required before implementation in Canada.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027804PMC
http://dx.doi.org/10.1212/WNL.0000000000002786DOI Listing

Publication Analysis

Top Keywords

als health
16
health care
16
care providers
16
pad
9
physician-assisted death
8
canada-wide survey
8
als
8
scc ruling
8
patients moderate
8
moderate severe
8

Similar Publications

Neural Stem/Progenitor Cell Therapy in Patients and Animals with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis.

Mol Neurobiol

January 2025

Hebei Medical University-Galway University Stem Cell Research Center, Hebei Medical University, Shijiazhuang, Hebei Province, 050017, China.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative malady that causes progressive degeneration and loss of motor neuron function in the brain and spinal cord, eventually resulting in muscular atrophy, paralysis, and death. Neural stem/progenitor cell (NSPC) transplantation can improve bodily function in animals and delay disease progression in patients with ALS. This paper summarizes and analyzes the efficacy and safety of neural stem/progenitor cell (NSPC) transplantation as a treatment for ALS, aiming to improve function and delay disease progression in patients.

View Article and Find Full Text PDF

[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment].

Nervenarzt

January 2025

Abteilung für Molekulares Neuroimaging, Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, 68159, Mannheim, Deutschland.

Background: Novel antidepressive substances are challenging the explanations for the mechanisms of action of traditional psychopharmacology.

Objective: What could be the shared effects of various antidepressants and in this context what role do extrapharmacological factors, such as the body and environment, play?

Material And Method: The available literature on clinical and preclinical data for assumed combined active factors of serotonergic psychedelic drugs, (es)ketamine, monoaminergic antidepressants and zuranolone are presented and the influence of context factors on the individual mechanisms of action is discussed.

Results: There are many indications that classical and novel pharmacological approaches could share similar mechanisms of action in the treatment of depression.

View Article and Find Full Text PDF

Objective: Tofersen, an antisense oligonucleotide, has recently received FDA and EMA approval for treating amyotrophic lateral sclerosis (ALS) in adults with SOD1 gene mutations. This systematic review and meta-analysis synthesized evidence on tofersen's safety and efficacy in patients with SOD1-related ALS.

Methods: A comprehensive search of three databases was conducted from inception through October 2024.

View Article and Find Full Text PDF

Introduction: Neurodevelopmental disorders, notably attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), present substantial challenges in mental health. Individuals referred for assessment in a psychiatric unit experience complex needs. This implies that their needs necessitate coordination across multiple sectors.

View Article and Find Full Text PDF

Background: Chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), and acute pulmonary edema (APE) are serious illnesses that often require acute care from prehospital emergency medical services (EMSs). These respiratory diseases that cause acute respiratory failure (ARF) are one of the main reasons for hospitalization and death, generating high health care costs. The prevalence of the main respiratory diseases treated in a prehospital environment in the prepandemic period and during the COVID-19 pandemic in Spain is unknown.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!